BioSpace News Archive

Castle Biosciences, Inc. today announced that it has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare” award in the seventh annual MedTech Breakthrough Awards program for its innovative TissueCypher® Barrett’s Esophagus test.

PDS Biotechnology Corporation, a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, will discuss its financial results for the quarter ended March 31, 2023, and provide a business update on its conference call.

POINT Biopharma Global Inc. and IONETIX Corporation announced a collaboration to create Ionetix Alpha Corp.

Illumina, a global leader in DNA sequencing and array-based technologies, issued a shareholder letter outlining the purpose-built mix of skills Illumina’s nominees bring to the Board compared to Carl Icahn’s unqualified associates, each of whom lack relevant experience and independence.

Thorne HealthTech, Inc. (“Thorne”) (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it is entering into a research and development partnership agreement with Arome Science, a leader in metabolomics, to develop a next-generation metabolomics test.

Dante Genomics, a global leader in genomics and precision medicine, today announced a free, initial feature of its platform agnostic proprietary B2B software to automatically turn FASTQ files to VCF files at no charge as an introduction to its AVANTI Software, demonstrating the broad scalability of its interpretation software to benefit sequencing labs of all sizes around the world.

Ikena Oncology, Inc. announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.55 per share.

ImmPACT Bio USA, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for IMPT-314, a potential first-in-class CD19/CD20 CAR T therapy for the treatment of patients with B-cell mediated malignancies.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023.

Pfizer Inc. announced that its wholly owned subsidiary, Pfizer Investment Enterprises Pte. Ltd., has commenced a multi-series offering of senior unsecured notes.